Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13461MR)

This product GTTS-WQ13461MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2&TNFRSF9 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001005862.3; NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 3604
UniProt ID P04626; Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13461MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13128MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ15975MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ4903MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ9442MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ11716MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ15013MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ11719MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ10955MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW